This content is machine translated Hodgkin's lymphoma No more transplants for relapsed or refractory HL in the future? The standard treatment approach for relapsed or refractory (RR) classical Hodgkin’s lymphoma (HL) after failure of first-line treatment is second-line therapy with the aim of achieving complete remission (CR), followed...…
View Post 3 min This content is machine translated Lymphoma Treatment goal: slow progression, improve quality of life Cancers of the lymphatic system affect around 1750 people in Switzerland every year. Intensive research has led to treatment becoming significantly more effective and tolerable in recent years. Even if…
View Post 4 min This content is machine translated Multiple Myeloma (MM) Prognostic factors, the role of leptin and MGUS in focus. Multiple myeloma results from the degeneration of a single plasma cell whose clones spread throughout the bone marrow. Overall, the disease occurs very rarely. However, it is one of the…
View Post 6 min This content is machine translated Blood cancer and co. Translational research and innovative treatment approaches At the transnational annual meeting of the German, Austrian and Swiss Societies for Hematology and Medical Oncology (DGHO), the latest data from basic, applied and translational research as well as…
View Post 4 min This content is machine translated Hodgkin's disease Excess mortality after surviving disease: a search for causes Today, more than 80% of all patients with Hodgkin lymphoma can be cured, and in early stages even more than 90%. Nevertheless, the disease and its therapy have a significant…
View Post 2 min This content is machine translated Excellent science Best Abstracts: the most important research results at a glance There is hardly any other discipline in which such great and rapid progress has been made as in oncology and hematology. As the studies honored as Best Abstracts demonstrate, immune…
View Post 8 min This content is machine translated ASH in Atlanta The throne wavers ECHELON-1 is the first positive data available on brentuximab vedotin in first-line Hodgkin lymphoma. And things are also progressing in CLL. Chemotherapy-free variants hold their own in recurrences.
View Post 4 min This content is machine translated Lymphomas What the family doctor needs to know At the SGIM Great Update in Interlaken, the most common problems and challenges that a family physician encounters when dealing with patients suffering from lymphoma were discussed. The only difficulty…
